S100A9 drives the chronification of psoriasiform inflammation by inducing IL-23/type 3 immunity.

[1]  T. Vogl,et al.  Interleukin 17 Promotes Expression of Alarmins S100A8 and S100A9 During the Inflammatory Response of Keratinocytes , 2021, Frontiers in Immunology.

[2]  J. C. Love,et al.  Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies , 2020, Immunity.

[3]  Katherine Li,et al.  Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. , 2019, The Journal of allergy and clinical immunology.

[4]  J. Roliński,et al.  Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis , 2018, Archivum Immunologiae et Therapiae Experimentalis.

[5]  M. Mahdavi,et al.  Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer , 2018, Inflammation Research.

[6]  V. Čokić,et al.  TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms , 2018, Cellular Oncology.

[7]  M. Sperandio,et al.  S100A8/A9: From basic science to clinical application. , 2016, Pharmacology & therapeutics.

[8]  T. Bieber,et al.  Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  H. Meng,et al.  The Pro-Apoptotic and Pro-Inflammatory Effects of Calprotectin on Human Periodontal Ligament Cells , 2014, PloS one.

[10]  D. Foell,et al.  Monocyte-Induced Development of Th17 Cells and the Release of S100 Proteins Are Involved in the Pathogenesis of Graft-versus-Host Disease , 2014, The Journal of Immunology.

[11]  Hugh A. Rand,et al.  Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody , 2014, The Journal of Immunology.

[12]  I. Bechmann,et al.  IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. , 2014, The Journal of investigative dermatology.

[13]  P. Tessier,et al.  DAMP Molecule S100A9 Acts as a Molecular Pattern to Enhance Inflammation during Influenza A Virus Infection: Role of DDX21-TRIF-TLR4-MyD88 Pathway , 2014, PLoS pathogens.

[14]  Raquel Navarro,et al.  S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. , 2013, Immunity.

[15]  Jennifer E Towne,et al.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. , 2013, The Journal of investigative dermatology.

[16]  B. Becher,et al.  Hiding under the skin: Interleukin-17–producing γδ T cells go under the skin? , 2012, Nature Medicine.

[17]  Mayte Suárez-Fariñas,et al.  Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis , 2012, The Journal of investigative dermatology.

[18]  J. Renauld,et al.  IL-22 Is Required for Imiquimod-Induced Psoriasiform Skin Inflammation in Mice , 2011, The Journal of Immunology.

[19]  V. Jala,et al.  Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. , 2011, Immunity.

[20]  W. Nacken,et al.  The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells , 2010, Nature Medicine.

[21]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[22]  T. Leanderson,et al.  Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides , 2009, PLoS biology.

[23]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[24]  Yihong Yao,et al.  Type I Interferon: Potential Therapeutic Target for Psoriasis? , 2008, PloS one.

[25]  Joachim Reischl,et al.  Increased expression of Wnt5a in psoriatic plaques. , 2007, The Journal of investigative dermatology.

[26]  D. Foell,et al.  Elevated serum levels of calcium‐binding S100 proteins A8 and A9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis , 2006, The British journal of dermatology.

[27]  W. Chazin,et al.  The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis , 2006, Arthritis research & therapy.

[28]  W. Nacken,et al.  Loss of S100A9 (MRP14) Results in Reduced Interleukin-8-Induced CD11b Surface Expression, a Polarized Microfilament System, and Diminished Responsiveness to Chemoattractants In Vitro , 2003, Molecular and Cellular Biology.

[29]  R. Donato,et al.  Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. , 1999, Biochimica et biophysica acta.

[30]  D. Zimmer,et al.  The S100 protein family: History, function, and expression , 1995, Brain Research Bulletin.